Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3849891 in MASLD with PNPLA3 I148M Genotype
NCT05395481Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2022
- Primary completion
- May 2026
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 3
01
Overview
Phase 1, randomised trial of LY3849891 in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of Participants with One or More Treatment Emergent Adverse Events at 26 weeks and Mean change from baseline on liver inflammation and fibrosis measured by MRI at 24 weeks. Started Jun 2022; status: completed.
02
Drugs
LY3849891
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT05395481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05395481.